Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer

Scandinavian Journal of Gastroenterology

Volumn 40, Issue 11, 2005, Pages 1343-1350

  Lagerholm, Sofia ^a,b   Lagerholm, Sara ^a,c   Dutta, Sudhir ^d,e   Nair, Padmanabhan ^a,c  

^a NonInvasive Technologies   (United States)

^b LUND INSTITUTE OF TECHNOLOGY   (Sweden)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d SINAI HOSPITAL OF BALTIMORE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; c erbb; c myc; Colon cancer; Non invasive detection; SCSR colonocytes

Indexed keywords

BETA ACTIN; COMPLEMENTARY DNA; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MYC PROTEIN;

ADULT; AGAR GEL ELECTROPHORESIS; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; INTESTINE CELL; MALE; ONCOGENE; ONCOGENE C ERB; ONCOGENE C MYC; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; BASE SEQUENCE; CASE-CONTROL STUDIES; COLON; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENES, MYC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROBABILITY; PROGNOSIS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SERUM RESPONSE FACTOR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 27844507560     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520510023549     Document Type: Article

References (28)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000. CA Cancer J Clin 2000;50:7-33.
2. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res 2001;7:1118-26.
3. Agency for Health Care Policy (AHCPR) Research activity. 1997;200:15-8.
4. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. N Natl Cancer Inst 1993;85:1311-8.
5. Ahlquist DA. Occult gastrointestinal bleeding. In: Yamada T, editor. Textbook of gastroenterology. New York: J.B. Lippincott and Co; 1995. pp 6669-721.
6. Macrae FA, St John JB, Caligiore P, Taylor LS, Legge JW. Optimal dietary conditions for Hemocult testing. Gastroenterology 1982;82:899-903.
7. Pasche B, Mulcahy M, Benson AB. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best practice and research. Clin Gastroenterol 2002;16:331-45.
8. Lowenfels AB. Fecal occult blood testing as a screening procedure for colorectal cancer. Ann Oncol 2002;13:40-3.
9. Kronborg O. Colon polyps and cancer. Endoscopy 2002;34:69-72.
10. Iyengar V, Albaugh G, Lohani A, Nair PP. Human stools as a source of viable colonic epithelial cells. FASEB J 1992;5:2856-9.
11. Albaugh G, Iyengar V, Lohani A, Malayeri M, Bala S, Nair PP. Isolation of exfoliated colonic epithelial cells, a novel non-invasive approach to the study of cellular markers. Int J Cancer 1992;52:347-50.
12. Nair PP, Lagerholm S, Dutta S, Shami S, Davis K, Shuzhen M, et al. Coprocytobiology: on the nature of cellular elements from stools in the pathophysiology of colonic disease. J Clin Gastroenterol 2003;36 Suppl 1:S84-93.
13. Desilets DJ, Davis KE, Nair PP, Salata KF, Maydonovitch BS, Howard RS, et al. Lectin binding to human colonocytes is predictive of colonic neoplasia. Am J Gastroenterol 1999;94:744-50.
14. Malayeri M, Albaugh G, Davis R, Bhathena S, Nair PP. Exfoliated human colonic epithelial cells: insulin binding and molecular cloning of the insulin receptor. Med Sci Res 1997;25:801-3.
15. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Sehoetz DJ, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-20.
16. Galandiuk S, Miseljic S, Yang AR, Early M, McCoy MD, Witliff JL. Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease. Arch Surg 1993;128:637-42.
17. Ishida H, Sadahiro S, Suzuki T, Ishikawa K, Tajima T, Makuuchi H. c-erbB-2 protein expression and clinicopathologic features in colorectal cancer. Oncol Reports 2000;7:1229-33.
18. Vizoso F, Villar C, Rodriguez JC, Raigoso P, Garcia-Mun JL, Allende MT. c-erbB-2 oncoprotein content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance. I. J Surg Invest 2000;1:483-93.
19. Slikowski M, du Bois R. HER-2/neu overexpression in colonic malignancies. Gastroenterology 2002;122:248-9.
20. Maurer C, Friess H, Kretschmann B. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998;29:771-7.
21. Shu M, Liu S, Yu P. Expression and significance of p53, c-erbb2, CEA proteins in colorectal adenoma and carcinoma. Hunan Yi Ke Da Xue Xue Bao 1998;23:129-31.
22. Ross JS, McKenna BJ. The HER2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
23. Mckay J, Loane J, Ross V, Ameyaw MM, Murray GI, Cassidy J, et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 2002;86:568-73.
24. Kaye M. Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer. Lung Cancer 2001;34:S43-S6.
25. Schuldiner O, Benvenisty N. A DNA microarray screen for genes involved in c-myc and N-myc oncogenesis in human tumors. Oncogene 2001;20:4984-94.
26. Lutz W, Leon J, Eilers M. Contributions of Myc to tumorigenesis. Biochim Biophys Acta 2002;1602:61-71.
27. Hann S, Eisenman R. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984;4:2486-97.
28. Greco C, Alvino S, Buglioni S, Assisi D, Capenta R, Grassi A, et al. Activation of c-myc and c-myb proto-oncogenes is associated with decreased apoptosis in tumor colon progression. Anticancer Res 2001;21:3185-92.